PATENT CLAIM ANALYSIS

Application Number: 15888948
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "184100"]

Abstract:
The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide. The technology further relates in part to methods for inducing partial apoptosis of cells that express an inducible modified caspase polypeptide, having a modified dose response curve to the multimeric ligand inducer. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide or the inducible modified caspase polypeptide, where the proportion of caspase polypeptide-expressing cells eliminated by apoptosis is related to the administered amount of the multimeric ligand inducer.

Claim (Index 2):
A method of controlling survival of transplanted therapeutic cells in a subject, comprising:\n a) preparing or obtaining therapeutic cells; b) transfecting or transducing a first subset of the therapeutic cells with a nucleic acid that encodes a chimeric polypeptide comprising a multimerization region and a first caspase-9 polypeptide, wherein the first caspase-9 polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9; c) transfecting or transducing a second subset of the therapeutic cells with a nucleic acid that encodes a chimeric polypeptide comprising a multimerization region and a second caspase-9 polypeptide, wherein the second caspase-9 polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and wherein the first caspase-9 polypeptide and the second caspase-9 polypeptide comprise different amino acid sequences; d) transplanting the transduced or transfected first subset of therapeutic cells and the second subset of therapeutic cells into the subject; and e) after (d), administering to the subject a multimeric ligand that binds to the multimerization region in an amount effective to kill more of the first subset of therapeutic cells than the second subset of therapeutic cells.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 88.0
- Lexical Diversity: 2.21739
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14296404', '15224441', '13792135', '14743384', '13112739']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7122102317594231
- 35 USC 102 Novelty (BERT): 0.7448837275094334
- Combined Prediction Score: 0.7154775813344242
- Mean Citation Score: 666.3747679999999
- Max Citation Score: 882.8988
- Similarity Product: 822.0875007280828

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test